A dynamic force in the fight against infectious diseases

Committed to protecting the world against dangerous and difficult-to-treat fungal pathogens.

Learn More

A ground-breaking advancement

Ibrexafungerp: our novel anti-fungal agent

Ibrexafungerp is an innovative new weapon for potential deployment against a range of serious fungal infections.

Learn More

Innovation in action

Life-Threatening Infections

We’re bringing new weapons to the fight against debilitating and life-threatening infections that pose serious challenges in hospitals.

Learn More

Serving Unmet Needs

Community Infections

Leveraging the abilities of our innovative oral antifungal therapy to help meet the needs of women suffering from fungal infections.

Learn More

Our pipeline

Our work on meaningful scientific breakthroughs has the power to change lives.

Learn More

Latest news

  • 03/30/23

    GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

    Read More >
  • 12/01/22

    SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

    Read More >
  • 11/30/22

    SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

    Read More >
  • 11/17/22

    SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

    Read More >
  • 11/09/22

    SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Read More >
  • 11/07/22

    SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi

    Read More >
  • 11/03/22

    Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

    Read More >
  • 11/01/22

    SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

    Read More >
  • 10/25/22

    Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer

    Read More >
  • 10/24/22

    SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

    Read More >

View All

Interested in learning more about our products, partnership opportunities and more?

Learn More

Make a Difference

Join Our Team

Our people are on a mission to cure infectious diseases and make a real difference in the lives of people around the world. Are you up for the challenge? Discover why you should join SCYNEXIS in the fight against fungal disease.

Learn More